| Name of the Instrument/Tool | Fibromyalgia Rapid Screening Tool (FiRST) |
| First Description |
Perrot S, Bouhassira D, Fermanian J; Cercle d'Etude de la Douleur en Rhumatologie. Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain. 2010 Aug;150(2):250-6. doi: 10.1016/j.pain.2010.03.034. Epub 2010 May 21. PMID: 20488620. |
| Year | 2010 |
| Domains | |
| Concept of constructs | Pain |
| Population/Disease | Disease specific |
| Originally developed for | Fibromyalgia (FM) |
| Other rheumatic diseases where can be applied (only if validated) |
Axial Spondyloarthritis, Osteoarthritis (OA), Rheumatoid Arthritis (RA) |
| Additional population with no rheumatic diseases |
No |
| Language: Originally published in | English/French |
| Available in Language | Turkish, French, Spanish, Portuguese, English, Greek |
| REFERENCE IDENTIFICATION | |
| Author/s | Perrot S, Bouhassira D, Fermanian J; Cercle d'Etude de la Douleur en Rhumatologie. |
| Title | Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). |
| Journal | Pain |
| Year | 2010 |
| Vol | 150 |
| Num | 2 |
| Pages | 250-5 |
| Country | France |
| Language | English |
| Other references of interest | |
| Link | https://pubmed.ncbi.nlm.nih.gov/27313278/ |
| Brief Description |
Performance of Fibromyalgia Rapid Screening Tool (FiRST) to detect fibromyalgia syndrome in rheumatic diseases. |
| Link | https://pubmed.ncbi.nlm.nih.gov/26814292/ |
| Brief Description |
The Discriminatory Ability of the Fibromyalgia Rapid Screening Tool (FiRST): An International Study in Spain and Four Latin American Countries |
| Link | https://pubmed.ncbi.nlm.nih.gov/30284078/ |
| Brief Description |
This study aims to evaluate the prevalence of FM in physicians in training using different screening tools and factors associated with its development. |
| Instrument/Tool Translations References | |
| Link | https://pubmed.ncbi.nlm.nih.gov/28265170/ |
| Brief Description |
Reliability and validity of the Turkish version of the Fibromyalgia Rapid Screening Tool (FiRST). |
| Link | https://pubmed.ncbi.nlm.nih.gov/27996191/ |
| Brief Description |
Validation of the Greek Version of the Fibromyalgia Rapid Screening Tool. |
| Link | https://pubmed.ncbi.nlm.nih.gov/24049098/ |
| Brief Description |
The Spanish version of the Fibromyalgia Rapid Screening Tool: translation, validity and reliability. Measurement properties of the Brazilian online version of the Fibromyalgia Rapid Screening Tool (FiRST): https://pubmed.ncbi.nlm.nih.gov/36316763/ |
| DEVELOPER CONTACT INFORMATION | |
| Correspondence to | S Perrot |
| serge.perrot@htd.aphp.fr | |
| Address | Service de Médecine Interne et Thérapeutique, INSERM U 987, Hôpital Hôtel Dieu, 1 Place du Parvis Notre Dame, 75004 Paris, France. |
| Website | --- |
| Available | --- |
| Links | --- |
| DESCRIPTION OF THE INSTRUMENT | |
| Type Of Measure | Questionnaire |
| Brief Description |
The Fibromyalgia Rapid Screening Tool (FiRST) is a brief, simple and straightforward self-administered questionnaire developed for the detection of fibromyalgia syndrome (FMS) in patients with diffuse chronic pain. It assesses widespread pain (item 1), fatigue (item 2), pain characteristics (item 3), non-painful abnormal sensations (item 4), functional somatic symptoms (item 5), sleep and cognitive problems (item 6). It is necessary to have the symptoms for the past 3 months at least. |
| Number of Items | 6 |
| Range | 0-6 |
| Responses options/scale |
Yes yes/no |
| Developed for | Clinical practice, Research |
| PRACTICAL APPLICATION | |
| Method of administration | Self-administered |
| Recommendations to score |
Items (1-6) need to be added. For each item, a score of 1 is given when the response is ‘‘Yes” and a score of 0 if the response is ‘‘No”. The total score is calculated as the sum of scores for the six items. |
| Score Interpretation | A score ≥5/6 has the highest sensitivity and specificity for fibromylagia. |
| Cut-off points | A cut-off score of 5 resulted in the highest proportion of correctly identified patients (87.9%). |
| Cut-off points applied to | Both |
| Smallest detectable change if described | --- |
| Smallest detectable change applied to | --- |
| Completion time by the patient | - minutes |
| Scoring time by the assessor | <3 minutes |
| Training to score | Not necessary |
| Strengths | Useful in clinical practice & research, Easy to use |
| Limitations | --- |
| OTHER COMMENTS | |
| Other Comments | --- |